Pharmafile Logo
Pharmafocus logo
Advanced Search

type 2 diabetes

Showing 15 posts of 46 posts found.

Novo’s Xultophy beats basal insulin in cutting cardiovascular risk

September 14, 2017
Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …

News
novo_flag

Novo diabetes drug outperforms Lilly rival at Phase 3

August 17, 2017
Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …

News
diabetes_injection

Type 2 diabetes directly linked to BMI

June 12, 2017
Research and Development, Sales and Marketing diabetes, type 2 diabetes

Research emerging from the American Diabetes Association’s meeting in San Diego has revealed that the likelihood of developing type 2 …

News

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

News
clinical_trial-web

Promising results for new type 2 diabetes management procedure

August 12, 2016
Research and Development, Sales and Marketing Fractyl, Revita, diabetes, type 2 diabetes

Fractyl Laboratories has revealed data from its first-in-human study of Revita duodenal mucosal resurfacing (Revita DMR), a new 60-minute, non-surgical …

News
novo_flag

Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients

June 14, 2016
Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes

Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …

News

Personalised care key to diabetes management, says NICE

December 2, 2015
Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes

UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

News
diabetes_injection

Sanofi’s LixiLan meets target in Phase III diabetes trial

September 16, 2015
Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes

Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …

News
fda_building

FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015
Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

News
google logo

Sanofi joins Google in diabetes tech push

September 1, 2015
Medical Communications Andy Conrad, Google life sciences, Sanofi, Type 1 diabetes, diabetes, google, type 2 diabetes

Google is continuing its work in diabetes, by teaming up with pharma giants Sanofi to create new digital technologies and …

News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …

News

Novo Nordisk pushes forward with new diabetes drug trial

July 13, 2015
Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes

Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …

News

Boehringer and Vitae Pharma drug fails in mid-stage trial

July 1, 2015
Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023